CLEVELAND, March 15, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the MRIdian Linac System, the company's next-generation MRIdian System, featuring linear accelerator (Linac) delivery. The MRIdian cobalt system received Shonin approval in August 2016.
MRIdian is the first and only MRI-guided radiation therapy system to receive Shonin approval in Japan, the world's third largest market for radiation oncology. One MRIdian cobalt system is currently treating in Tokyo at the National Cancer Center (NCC) and one is under installation at the private Edogawa Hospital.
The MRIdian Linac System combines MR imaging with linear accelerator radiation delivery so clinicians can visualize the tumor and nearby soft tissue and organs in real-time. Like the MRIdian cobalt system, MRIdian Linac enables daily on-table adaptive radiotherapy and real-time tracking to adjust radiation beam delivery dynamically for subtle anatomical changes that may occur, both during treatment delivery and throughout the course of treatment. Combined, these capabilities provide the potential for clinicians to improve targeting precision and thus deliver higher radiation doses.
Ad Statistics
Times Displayed: 112999
Times Visited: 6736 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
ViewRay is represented in Japan by ITOCHU Corporation, one of the three largest general trading companies in Japan. ITOCHU has been focusing on the healthcare business to promote important medical innovations in Japan for approximately 40 years.
"In collaboration with our partner ITOCHU Corporation, we're excited to expand the MR image-guided radiation therapy solutions available to clinicians in Japan to now include MRIdian Linac," said Chris A. Raanes, president and chief executive officer of ViewRay. "The regulatory approval of MRIdian Linac in Japan, a market that highly values advanced medical technologies, is an important milestone in the System's global adoption."
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges including beam distortion, skin toxicity, and other safety concerns, which may potentially occur when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
SOURCE ViewRay, Inc.
